ArrePath was founded upon the mission to discover new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.

We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues.

Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.

Biotechnology

ArrePath

Kurt Thorn

Fei Shen

Dylan Morris

The Board Members and Advisors at ArrePath provide strategic guidance, governance, and expert insights to drive the company's mission of discovering new classes of anti-infectives. They leverage their extensive experience and networks to support the executive team in decision-making, ensuring alignment with scientific and business objectives to combat antimicrobial resistance using advanced imaging and AI/ML technologies.

Board Members and Advisors

About

Team members

Other teams at ArrePath

Science and Research Team

Leadership Team